PPD flips the patient enrollment model and launches new site solution

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/Jirsak)
(Image: Getty/Jirsak)
PPD has launched a new site solution for enrolling patients in clinical studies as it proposes enrolling patients first – before activating sites – via a new enrollment model.

Acurian, a patient enrollment and retention solutions provider, and the research site network Synexus have launched SynexusPlus, an integrated site solution for enrolling patients in clinical studies. 

The companies are part of Accelerated Enrollment Solutions​ (AES), a business unit of the contract research organization (CRO) PPD​, which introduced the offering at the DIA 2018 Global Annual Meeting last week.

According to the companies, the SynexusPlus site network provides a “closed-loop process,”​ which can be customized to specific study requirements.

Under the offering, trial budgets will incorporate all recruitment, site, investigator grant, and other fees from Synexus and Acurian into a single price per patient.

Roger Smith, senior vice president and general manager of AES said:

“Through this collaborative effort between these leaders in their respective fields, we can package and prioritize all of the components of site and enrollment conduct, and more precisely control the enrollment of study participants for a new standard in clinical trial productivity.”

Inverting the patient enrollment model

PPD also recently introduced a new patient enrollment model, dubbed PatientAdvantage.

According to the CRO, the approach inverts traditional clinical trial delivery steps by first, identifying potential participants, before delivering qualified patients to investigative sites for enrollment.

“Instead of that traditional site-first approach, PatientAdvantage enables us to start by rapidly enrolling community-based patients from our proprietary databases and modeling,”​ said Smith.

“Then, after mapping patient locations, we select sites to match patient-rich populations. This patient-centric solution is highly predictive and yields greater enrollment and budget certainty," ​he said.

Related news

Show more

Related products

show more

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Baxter’s Oncology Contract Manufacturing

Baxter’s Oncology Contract Manufacturing

Baxter BioPharma Solutions | 29-Aug-2018 | Product Brochure

Baxter BioPharma Solutions’ FOYA award-winning facility in Halle/Westfalen, Germany, offers state-of-the-art parenteral cGMP manufacturing at one location,...

Related suppliers

Follow us

Products

View more

Webinars